This is a repository copy of *Is peer support in group clinics as effective as traditional individual appointments? The first study in patients with Celiac disease.*

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/156922/

Version: Published Version

**Article:**
Rej, A., Trott, N., Kurien, M. orcid.org/0000-0002-4227-9500 et al. (4 more authors) (2020)
Is peer support in group clinics as effective as traditional individual appointments? The first study in patients with Celiac disease. Clinical and Translational Gastroenterology, 11 (1). e00121.

10.14309/ctg.0000000000000121

**Reuse**
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can’t change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Is Peer Support in Group Clinics as Effective as Traditional Individual Appointments? The First Study in Patients With Celiac Disease

Anupam Rej, MBChB, BMedSci, MRCP1, Nick Trott, RD, MSc1, Matthew Kurien, MBChB, MRCP, MD1,2, Federica Branchi, MD1,3, Emile Richman, BSc, MSc4, Sreedhar Subramanian, MD, MRCP4, and David Surendran Sanders, MBChB, MRCP, MD, FACG, FRCP1,2

INTRODUCTION: Celiac disease (CD) is common, affecting approximately 1% of the population. The cornerstone of management is a gluten-free diet, with dietetic advice being the key to aiding implementation. The aim of the study was to assess group clinics in comparison with traditional individual appointments.

METHODS: Patients with a new diagnosis of CD, confirmed histologically, were prospectively recruited over 18 months in Sheffield, United Kingdom. Patients received either a group clinic or traditional one-to-one appointment, led by a dietitian. Quality-of-life questionnaires were completed at baseline, as well as biochemical parameters being recorded. Patients were followed up at 3 months, where adherence scores were assessed as well as biochemical parameters and quality of life questionnaires being completed.

RESULTS: Sixty patients with CD were prospectively recruited and received either an individual (n = 30) or group clinic (n = 30). A statistically significant reduction in tissue transglutaminase was noted following group clinics (mean 58.5, SD 43.4 U/mL vs mean 13.2, SD 5.7 U/mL, P < 0.01). No significant differences in baseline and follow-up biochemical parameters between one-to-one and group clinics were noted. At follow-up, there was no statistically significant difference between mean gluten-free diet adherence scores (mean 3.1, SD 0.4 vs mean 3.1, SD 0.7, P = 0.66) between one-to-one and group clinics.

DISCUSSION: This first study assessing group clinics in CD demonstrates they are as effective as traditional one-to-one clinics, with the added benefits of peer support and greater efficiency, with an estimated 54% reduction of dietetic resources.
Currently, celiac dietetic advice is provided by one-to-one appointments. However, dietetic group clinics have been proposed as a new method to manage these patients (12). Potential benefits of this approach include the ability for peer support, with peer support having been shown to improve outcomes in patients with both diabetes and hypertension (13–15). The effectiveness of group clinics has also been demonstrated in the field of gastroenterology, in particular group clinics for the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyol diet in patients with irritable bowel syndrome (16). The rise in diagnosis of CD has also resulted in an increased demand in healthcare services and led to a strain on existing resources. There appears to be a wide variation in the provision of dietetic services for CD in the United Kingdom, with many centres failing to deliver the required provision as suggested by UK national guidelines (17). Group clinics may provide an opportunity to standardize dietetic care in CD, both in the United Kingdom and globally.

Although there are several potential benefits of group clinics, little is known on its efficacy for patients with newly diagnosed CD in comparison with traditional one-to-one appointments. As a result of this, this study aimed to assess the outcomes of the novel set up of group clinics in comparison with traditional one-to-one clinics for the first time in CD.

METHODS

Study design and patients

Participants were prospectively recruited and allocated over an 18-month period through referrals from primary and secondary care to the dietetic service at Sheffield Teaching Hospitals, United Kingdom. Participants were recruited for group clinics initially. After this, participants were recruited for one-to-one clinics. The study ceased once 30 participants had been recruited for both group and one-to-one clinics. Participants were not given a choice in allocation to intervention.

Patients older than 18 years with newly diagnosed celiac disease were recruited, as defined as a either a positive immunoglobulin A (IgA)-tissue transglutaminase (TTG) or IgA-endomysial antibody (EMA) in conjunction with biopsy-proven CD (Marsh 3a or above). Patients with multiple diagnoses (e.g., Crohn’s disease, ...
ulcerative colitis, and diabetes mellitus), communication barriers, and who had specifically requested an individual clinic were excluded.

The median group size was 6 participants (minimum 4, maximum 9; total 5 groups). The same topics were covered in group clinics vs one-to-one appointments and included education on a GFD, prescriptions, traveling, and information on Coeliac UK (Figure 1). Both sessions relied on discussion with the dietitians with PowerPoint presentations.

All patients had nutritional assessments at baseline (first appointment) and bloods performed in line with British Society of Gastroenterology guidelines. Baseline demographics, celiac serology (IgA-EMA and IgA-TTG), hemoglobin, adjusted calcium, vitamin D, vitamin B12, folate, and ferritin levels were recorded. Validated questionnaires were completed at baseline, which were the Short-Form 36 (SF-36) survey (18) and Hospital Anxiety and Depression Score (HADS) (19).

### Table 2. Comparison of biochemical markers, adherence scores and questionnaire data between one-to-one clinics and group clinics at baseline and follow-up

|                       | Baseline One-to-one clinics (n = 30) | Group clinics (n = 30) | P value | Follow-up One-to-one clinics (n = 30) | Group clinics (n = 30) | P value | Baseline vs follow-up One-to-one clinics (n = 30), P value | Group clinics (n = 30), P value |
|-----------------------|-------------------------------------|-----------------------|---------|--------------------------------------|-----------------------|---------|----------------------------------------------------------|---------------------------------|
| Biochemical markers   |                                     |                       |         |                                      |                       |         |                                                          |                                 |
| EMA                   |                                     |                       |         |                                      |                       |         |                                                          |                                 |
| Positive, n (%)       | 30 (100.0)                          | 27 (90.0)             | N/A     | 12 (40.0)                            | 8 (28.6)              | 0.67    | <0.01                                                   | <0.01                           |
| Negative, n (%)       | 0 (0.0)                             | 3 (10.0)              |         | 18 (60.0)                            | 20 (71.4)             |         |                                                          |                                 |
| TTG (U/mL), mean ± SD | 71.0 ± 43.5                         | 63.4 ± 45.2           | 0.51d   | 22.1 ± 36.9                          | 13.2 ± 15.7           | 0.25g   | <0.01                                                   | <0.01                           |
| Hemoglobin (g/dL),    | 135.4 ± 13.1                        | 142.1 ± 13.7          | 0.06d   | 134.1 ± 23.7                         | 133.2 ± 35.2          | 0.92g   | 0.73                                                    | 0.45                            |
| Ferritin (µg/L),      | 64.1 ± 65.3                         | 99.4 ± 140.3          | 0.22d   | 70.1 ± 82.1                          | 126.8 ± 172.5         | 0.11d   | 0.44                                                    | 0.21                            |
| B12 (ng/L), mean ± SD | 363.7 ± 163.3                       | 326.3 ± 122.5         | 0.32d   | 452.6 ± 339.1                       | 392.8 ± 186.6         | 0.41d   | 0.19                                                    | 0.08                            |
| Folate (µg/L), mean ± SD | 9.9 ± 6.6                        | 8.2 ± 3.9             | 0.21d   | 11.2 ± 4.9                           | 11.6 ± 4.8            | 0.72d   | 0.31                                                    | <0.01                           |
| Vitamin D (nmol/L),   | 62.9 ± 30.3                         | 52.6 ± 27.9           | 0.20d   | 74.4 ± 23.2                          | 75.3 ± 28.9           | 0.90d   | <0.01                                                   | <0.01                           |
| Adjusted calcium      | 2.3 ± 0.1                           | 2.3 ± 0.1             | 0.53d   | 2.4 ± 0.1                            | 2.3 ± 0.1             | 0.38d   | 0.03                                                    | 0.26                            |
| Adherence questionnaire|                                     |                       |         |                                      |                       |         |                                                          |                                 |
| Biagi adherence score, | 3.1 ± 0.4                           | 3.1 ± 0.7             | 0.66d   | 3.0 ± 0.3                            | 3.0 ± 0.3             |         |                                                          |                                 |
| Questionnaire data    |                                     |                       |         |                                      |                       |         |                                                          |                                 |
| SF-36 physical summary, mean ± SD | 45.8 ± 9.6                  | 47.3 ± 9.3           | 0.54d   | 47.3 ± 8.9                           | 45.8 ± 9.2            | 0.52d   | 0.19                                                    | 0.35                            |
| SF-36 mental summary, mean ± SD | 46.5 ± 9.8                  | 44.6 ± 10.9          | 0.47d   | 46.4 ± 9.5                           | 44.8 ± 11.8           | 0.57d   | 0.91                                                    | 0.84                            |
| HADS anxiety, mean ± SD | 6.1 ± 4.0                        | 7.6 ± 4.8             | 0.18d   | 5.3 ± 3.1                            | 7.6 ± 4.9             | 0.04d   | 0.17                                                    | 0.94                            |
| HADS depression, mean ± SD | 4.2 ± 3.4                        | 4.8 ± 3.8             | 0.52d   | 3.8 ± 3.4                            | 4.8 ± 4.1             | 0.32d   | 0.47                                                    | 1.00                            |

EMA, endomysial antibody; HADS, Hospital Anxiety and Depression; SF-36, Short-Form 36; TTG, tissue transglutaminase.

*Pair test.

**Independent samples t-test.

*Missing values n = 28.

*Chi² test.

*Mean ± SD.

*Missing values n = 27.

*Mean ± SD.

*Comparison of biochemical markers, adherence scores and questionnaire data between one-to-one clinics and group clinics at baseline and follow-up.
After this, all patients were re-evaluated at a 3-month follow-up appointment. At this point, adherence was assessed using a validated questionnaire (Biagi score), as well as celiac serology (IgA-EMA, IgA-TTG), hemoglobin, adjusted calcium, vitamin D, vitamin B12, folate, and ferritin levels being recorded. SF-36 survey and HADS were once again completed. Figure 2 outlines the study flow.

**Celiac serology**
Enzyme-linked immunosorbent assay kits (Aesku Diagnostics, Wendelsheim, Germany) were used to assay TTG antibodies. A TTG titer of >7 U/mL was regarded as positive as per manufacturer’s guidance. IgA-EMA was detected by immunofluorescence on oesophageal sections (Binding Site, Birmingham, United Kingdom). Total IgA was measured using Behring BN2 nephelometer (Haywards Heath, West Sussex, United Kingdom).

**Dietary adherence questionnaire**
A validated questionnaire was used devised by Biagi et al. (20), which is made of 5 levels (0–4). Scores of 0 or 1 were defined as not following a strict GFD; score of 2 was defined as following a GFD but with important errors that require correction. Patients with a score of 3 or 4 were defined as following a strict GFD.

**Ethical considerations**
The study protocol was approved by the Yorkshire and Humber Research Ethics committee and registered with the local research and development department of Sheffield Teaching Hospital NHS Foundation Trust (REC reference 14/TH/1216). Written consent was obtained from all patients.

**Statistical analysis**
All data were analyzed using SPSS version 24 (International Business Machines, Armonk, NY). Data were summarized using descriptive statistics, including counts and percentages for categorical data and mean ± SD for continuous data. Paired t tests were used to compare continuous data within groups, with the independent t test to compare continuous data between groups. Comparison between categorical data between both groups was performed using x^2 testing. Statistical significance was considered when P < 0.05.

**RESULTS**
A total of 87 patients with newly diagnosed CD were prospectively recruited and allocated for a dietetic consultation between December 2014 and August 2016. Of these, 16 patients (18.4%) failed to attend their first appointment, with 11 patients (12.6%) failing to attend their follow-up appointment. Of the remaining 60 patients (n = 39 female, mean age 48.2 ± 16.1 years), 30 patients were seen in group clinics and 30 had one-to-one appointments (Figure 2).

The demographics of all patients are outlined in Table 1. There was no difference in baseline age (P = 0.24), weight (P = 0.12), body mass index (P = 0.05), time seen from initial diagnosis (P = 0.84), or follow-up duration (P = 0.19) between group clinic patients and one-to-one appointment patients.

Table 2 shows the outcomes of patients after being seen in the both one-to-one and group clinics. The mean duration of follow-up in group clinics was 12.6 ± 2.2 weeks. A statistically significant reduction in TTG was noted after group clinics (63.4 ± 43.4 U/mL vs 13.2 ± 15.7 U/mL, P < 0.01), as well as an increase in folate levels (8.2 ± 3.9 µg/L vs 11.6 ± 4.8 µg/L, P < 0.01) and vitamin D levels (52.6 ± 27.9 nmol/L vs 75.3 ± 28.9 nmol/L, P < 0.01). No differences in hemoglobin, ferritin, B12, adjusted calcium, SF-36, and HADS were noted after being seen in a group clinic.

The mean duration of follow-up in one-to-one clinics was 16.1 ± 14.5 weeks. A statistically significant reduction in TTG was noted after one-to-one clinics (71.0 ± 43.5 U/mL vs 22.1 ± 36.9 U/mL, P < 0.01), as well as an increase in vitamin D levels (62.9 ± 30.3 nmol/L vs 74.4 ± 23.2 nmol/L, P < 0.01) and adjusted calcium levels (2.3 ± 0.1 mmol/L vs 2.4 ± 0.1 mmol/L, P < 0.01). No differences in hemoglobin, ferritin, B12, folate, SF-36, and HADS were noted after being seen in a group clinic.

There was no significant difference in baseline and follow-up biochemical parameters, between one-to-one and group clinics, as seen in Table 2. At follow-up, there was no statistically significant difference between mean GFD adherence scores (3.1 ± 0.4 vs 3.1 ± 0.7, P = 0.66) between one-to-one and group clinics. The HADS Anxiety score was higher in the group clinics vs one-to-one clinics at follow-up (7.6 ± 4.9 vs 5.3 ± 3.1, P = 0.04). No other differences in baseline and follow-up SF-36 and HADS scores were noted between one-to-one and group clinics.

The potential time savings of a group clinic were calculated, as seen in Table 3. Time savings were based on the length of the group clinic being estimated at 90 minutes, in comparison with 60 minutes for a one-to-one appointment, with an average of 6 patients per group clinic. As can be seen from Table 3, the estimated time savings for group clinics was 28 hours (54% reduction).

**DISCUSSION**
Our findings support that dietetic led intervention is effective for the management of newly diagnosed CD. This is the first study to demonstrate that group clinics are as effective as one-to-one clinics in the delivery of CD dietetic advice in patients with newly diagnosed CD. Both dietetic interventions led to similar adherence at follow-up, with improvement in noninvasive serological markers, with no difference between groups. Although serological markers and questionnaires were used to assess adherence in addition to the dietary review, it is known that serology may not accurately predict mucosal recovery (21), as well as patients being seen at relatively short-term follow-up. Nonetheless, the Biagi score is a validated score to assess adherence in CD (20), with

| Table 3. Time comparison of group vs one-to-one clinics (n = 30 per group) |
|---|---|
| Actual time spent for one-to-one clinics | Estimated equivalent time for one-to-one clinic |
| Patient education (hr) | 7.5 | 30.0 |
| Resource development (hr) | 14.0 | 14.0 |
| Postclinic documentation (hr) | 2.0 | 7.5 |
| Total hours | 23.5 | 51.5 |
Internationally, dietetic advice (GFD) for patients with CD is more efficient than one-to-one clinics, suggesting strict adherence for patients in both groups. This highlights that group clinics are likely to result in strict GFD adherence for patients with CD.

Nutritional adequacy can be a concern on the implementation of GFD (22), with this study noting no difference between groups with regards to B12, folate, ferritin, and adjusted calcium. Quality-related measures of life were also not different between groups, other than noting that individuals having one-to-one appointments had a statistically significantly lower HADS anxiety scores than group therapy at follow-up. However, this is unlikely to be of clinical significance as the mean HADS scores in both one-to-one and group clinics were below 8, which is the threshold for probable anxiety or depression (19). It is also important to note that there were no changes seen in other quality of life parameters. There were significant improvements in folate and vitamin D levels after patients received group therapy, as well as reductions in TTG levels. This highlights that group therapy may beneficially improve these parameters. It must be noted that these findings for group clinics were seen at a mean follow-up 12.6 ± 2.2 weeks. It is therefore unclear whether these parameters would be maintained at a longer follow-up period, with further research required to assess long term biochemical parameters in individuals with CD receiving advice via group clinics.

The overall findings of this study are in line with similar methods used for other dietetic clinics, such as the low fermentable oligo-saccharides, disaccharides, monosaccharides, and polyols approach, where group clinics have been shown to be as effective as one-to-one advice (16). This has also been seen in type 2 diabetes, which has demonstrated group based self-management education to be as effective as routine management (15). In addition to group clinics showing equally efficacious to traditional individual appointments, there is also likely to be the added benefit of peer-to-peer support provided by group clinics, which is not available in individual appointments. Also, face-to-face social networks have been shown to be associated with higher quality-of-life scores in patients with CD, which group clinics provide (23). It also appears that group clinics are a cost-effective intervention, with a 54% reduction in the number of dietetic hours required to deliver this service.

The strength of this study includes its methodology. Patients with a diagnosis of confirmed CD through serological and histological markers were only included, with patients with multiple diagnoses excluded. This ensured that the changes seen after dietetic advice were a result of CD management, rather than a result of other coexistent pathology, such as diabetes mellitus. Also, the dietary advice given to patients was uniform, preventing bias.

A potential limitation of the study was that this study was performed in a tertiary center. As this study was performed in one specialized unit in the United Kingdom, it may not be applicable to other centers, which may differ in dietary expertise. However, the information given in clinics was standardized, with the aim of generalizability of care for these patients and to reduce geographical variation, which is currently occurring, as seen from the survey from Coeliac UK on the provision of dietary services (17). However, further studies assessing group therapies in CD in the United Kingdom and globally, with collaboration between different centres, may help standardization of care further. Also, patient and public involvement may help facilitate this.

This first study assessing group clinics in newly diagnosed CD demonstrates that this is a cost-saving intervention, with an estimated 54% reduction in dietetic resources, with no detriment to patient education and GFD adherence. Group clinics also provide the added benefits of peer support, and are likely to be beneficial globally, with further studies required to assess this.

CONFLICTS OF INTEREST

Guarantor of the article: David Surendran Sanders, MBChB, MRCP, MD, FACC, FRCP.

Specific author contributions: N.T. collected the data for the study. A.R., N.T., M.K., F.B., and D.S.S. drafted the manuscript. All authors approved the final manuscript.

Financial support: A grant for this research was received from Coeliac UK.

Potential competing interests: D.S.S. receives an educational grant from Schaer (a gluten-free food manufacturer). Dr. Schaer did not have any input in drafting of this manuscript. The remaining authors disclose no conflicts of interest.

Ethical approval: REC reference 14/YH/1216.

Study Highlights

WHAT IS KNOWN

- Internationally, dietetic advice (GFD) for patients with CD is delivered by dietitians on a one-to-one basis.
- Group clinics have been demonstrated to be effective in other medical conditions but have yet to be assessed in CD.

WHAT IS NEW HERE

- Group clinics have been shown to be as effective as individual appointments in CD.
- Peer support is an added benefit of group clinics.
- Group clinics are more efficient than one-to-one appointments, with a 54% reduction in dietetic resources.

REFERENCES

1. Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013;62(1):43–52.
2. Rubio-Tapia A, Ludvigsson JF, Brantner TL, et al. The prevalence of celiac disease in the United States. Am J Gastroenterol 2012;107(10):1538–44; quiz 1537, 1545.
3. Chong RS, Larson SA, Khaleghi S, et al. Prevalence and morbidity of undiagnosed celiac disease from a community-based study. Gastroenterology 2017;152(4):830–9.e5.
4. Chong RS, Unalp-Arida A, Ruhl CE, et al. Less hidden celiac disease but increased gluten avoidance without a diagnosis in the United States: Findings from the National Health and Nutrition Examination Surveys from 2009 to 2014. Mayo Clin Proc 2016. [Epub ahead of print December 5, 2016.]
5. West J, Fleming KM, Tata LJ, et al. Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: Population-based study. Am J Gastroenterol 2014;109(5):757–68.
6. Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet 2018; 391(10115):70–81.
7. Green PH, Fleischauer AT, Bhagat G, et al. Risk of malignancy in patients with celiac disease. Am J Med 2003;115(3):191–5.
8. Olmos M, Antelo M, Vazquez H, et al. Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease. Dig Liver Dis 2008;40(1):46–53.
9. Barratt SM, Leeds JS, Sanders DS. Quality of life in Coeliac disease is determined by perceived degree of difficulty adhering to a gluten-free diet, not the level of dietary adherence ultimately achieved. J Gastrointestin Liver Dis 2011;20(3):241–5.
10. Hall NJ, Rubin G, Charnock A. Systematic review: Adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009;30(4):315–30.
11. Bebb JR, Lawson A, Knight T, et al. Long-term follow-up of coeliac disease—What do coeliac patients want? Aliment Pharmacol Ther 2006; 23(6):827–31.
12. Oldale C. Managing increased diagnosis of coeliac disease through group education. NHM Mag 2013;81:12–3.
13. Fisher EB, Boothroyd RI, Coufal MM, et al. Peer support for self-management of diabetes improved outcomes in international settings. Health Aff (Millwood) 2012;31(1):130–9.
14. Krishnamoorthy Y, Sakhivel M, Sarveswaran G, et al. Effectiveness of peer led intervention in improvement of clinical outcomes among diabetes mellitus and hypertension patients: A systematic review and meta-analysis. Prim Care Diabetes 2019;13(2):158–69.
15. Steinsbekk A, Rygg LØ, Lisulo M, et al. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus: A systematic review with meta-analysis. BMC Health Serv Res 2012;12:213.
16. Whigham L, Joyce T, Harper G, et al. Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome. J Hum Nutr Diet 2015;28(6): 687–96.
17. Nelson M, Mendoza N, McGough N. A survey of provision of dietetic services for coeliac disease in the UK. J Hum Nutr Diet 2007;20(5): 403–11.
18. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473–83.
19. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale—A review of validation data and clinical results. J Psychosom Res 1997;42(1):17–41.
20. Biagi F, Bianchi PI, Marchese A, et al. A score that verifies adherence to a gluten-free diet. A cross-sectional, multicentre validation in real clinical life. Br J Nutr 2012;108(10):1884–8.
21. Vahedi K, Mascart F, Mary Y, et al. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol 2003;98(5):1079–87.
22. Vici G, Belli L, Biondi M, et al. Gluten free diet and nutrient deficiencies: A review. Clin Nutr 2016;35(6):1236–41.
23. Lee AR, WolfR, Contento I, et al. Coeliac disease: The association between quality of life and social support network participation. J Hum Nutr Diet 2016;29(3):383–90.

Open Access This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.